Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III)

Exclusion Criteria

• •Fever within 3 days before vaccination (body temperature ≥ 38 degrees Celsius) Persons with congenital malformations, neurological disorders, psychiatric disorders or families with neurological or psychiatric conditions or brain damage.
• •Having abnormal immune status or being treated for immunological control; Being immunocompromised as a result of progressive disease treatment.
• •Have received immunosuppressive drugs (steroid group) for more than 2 weeks before starting the vaccination.
• •Allergy to any vaccine component including hypersensitivity reactions and anaphylactic shock to the antibiotics (Kanamycine and Erythromycin), egg products and gelatin.
• •Family history of immunodeficiency.
• •Have a history of high fever, seizures
• •premature birth (\<37 weeks) (applicable to children 1-2 years).
• •Malnutrition level 3 or above (applicable to children 1-2 years).
• •Have used of gamma globulin, blood transfusions within 3 months before vaccination or gamma glubolin in large doses or the use of immunosuppressive drugs within 6 months before vaccination
• •Have used live vaccines within 27 days before vaccination; Have used other vaccines within 4 weeks before entry to study; Use of immunoglobulins or blood products within 3 months before vaccination;
• •Is participating in trial other drugs or vaccines; Has an acute or chronic disease that affects the safety (including but not limited to: chronic liver disease, some kidney disease, progressive or unstable neurological disorders, diabetes and organ transplants).
• •Having serious acute illness. Responsible doctor or doctor in charge of evaluation consider as unsuitable, such as having abnormal crying ...
• •Having plan to go far from the study site between visits. - Being pregnant (for women aged 14 - 45 years)